Base de dados : LILACS
Pesquisa : D12.644.276.374.200.110.990.600 [Categoria DeCS]
Referências encontradas : 17 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 17 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975013
Autor: Chami, Vitória de Oliveira; Nunes, Livia; Capelli Júnior, Jonas.
Título: Expression of cytokines in gingival crevicular fluid associated with tooth movement induced by aligners: a pilot study
Fonte: Dental press j. orthod. (Impr.);23(5):41-46, Sept.-Oct. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction: The search for more aesthetic and comfortable orthodontic devices has led to an increase in the use of clear aligners. Objective: To increase knowledge on biological mechanisms of orthodontic tooth movement using Invisalign aligners. Methods: This study included 11 patients with a mean age of 23.6 ± 4.8 years. Cases planning included alignment and leveling of lower incisors using Invisalign aligners. Gingival crevicular fluid samples were collected from the lower incisors on the day of delivery of aligner number 1 (T0) and after 1 (T24h), 7 (T7d), and 21 (T21d) days. During the observation period of the study, the patients used only the aligner number 1. Levels of nine cytokines were quantified using Luminex's multi-analysis technology. Non-parametric tests were used for comparisons between cytokine expression levels over time. Results: Cytokine expression levels remained constant after 21 days of orthodontic activation, except those of MIP-1β, which presented a statistical difference between T24h and T21d with a decrease in the concentration levels. IL-8, GM-CSF, IL-1β, MIP-1β, and TNF-α showed the highest concentrations over time. Conclusions: The different behavior in the levels of the investigated cytokines indicates a role of these biomarkers in the tissue remodeling induced by Invisalign.

RESUMO Introdução: a busca por dispositivos ortodônticos mais estéticos e confortáveis gerou um aumento no uso de alinhadores transparentes. Objetivo: ampliar o conhecimento sobre os mecanismos biológicos associados ao movimento dentário ortodôntico promovido por alinhadores Invisalign®. Métodos: a amostra foi constituída por 11 pacientes, com idade média de 23,6 ± 4,8 anos. O planejamento dos casos incluiu alinhamento e nivelamento de incisivos inferiores usando os alinhadores. O fluido gengival crevicular foi coletado na superfície vestibular de incisivos inferiores no dia da entrega do alinhador número 1 (T0) e após 1 (T24h), 7 (T7d) e 21 (T21d) dias. Durante o período de observação do estudo, os pacientes utilizaram apenas o alinhador número 1. Os níveis de nove citocinas foram quantificados por meio do sistema Luminex de multianálise. Testes não paramétricos foram realizados para comparações entre os níveis de expressão de citocinas ao longo do tempo. Resultados: a concentração das citocinas manteve-se constante após 21 dias de ativação ortodôntica, exceto a MIP-1β, que apresentou uma redução estatisticamente significativa entre os tempos T24h e T21d. As IL-8, GM-CSF, IL-1β, MIP-1β e TNF-α apresentaram as maiores concentrações ao longo do tempo. Conclusão: a constância na expressão dos níveis das citocinas parece estar compatível com o estímulo mecânico induzido por alinhadores.
Descritores: Técnicas de Movimentação Dentária
Citocinas/análise
Líquido do Sulco Gengival/química
-Aparelhos Ortodônticos Removíveis
Citocinas/metabolismo
Fator Estimulador de Colônias de Granulócitos e Macrófagos/análise
Interleucina-8/análise
Fatores Estimuladores de Colônias/análise
Interleucina-7/análise
Fator de Necrose Tumoral alfa/análise
Quimiocina CCL2/análise
Interleucina-17/análise
Interleucina-1beta/análise
Quimiocina CCL4/análise
Incisivo
Limites: Humanos
Masculino
Feminino
Adulto Jovem
Responsável: BR1.1 - BIREME


  2 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-840845
Autor: Pastore, Valentina; Bartoli, Fabio.
Título: Urinary excretion of EGF and MCP-1 in children with vesico-ureteral reflux
Fonte: Int. braz. j. urol;43(3):549-555, May.-June 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose The aim of this study was to investigate the urinary concentration of epidermal growth factor (EGF) and monocyte chemotactic protein-1 (MCP-1) as reflux nephropathy (RN) biomarkers before and after endoscopic treatment of moderate to severe vesico-ureteral reflux (VUR). Materials and methods A prospective study was carried out on 72 children with moderate to severe VUR. All patients underwent endoscopic treatment using Macroplastique® or Deflux®. Vesico-ureteral reflux resolution was tested by post-operative voiding cystourethrography after 3 months and 2 years. Follow-up urinary samples were collected at that time. Control samples were taken from healthy children with no clinical evidence of renal and bladder disease and no history of UTI. Results In VUR patients, pre-operative urinary EGF levels had a down-regulation when compared to controls. Following successful VUR repair, urinary EGF levels of VUR children progressively increased only at long term follow-up but without returning to normal levels. Urinary MCP-1 levels were highly expressed in pre-operative samples and decreased markedly during early post-operative measurements. Urinary MCP-1 levels did not further decreased in late post-operative follow-up. In fact, these levels remained significantly higher when compared to controls. Conclusions Urinary levels of EGF and MCP-1 may become useful markers for monitoring the response to surgical treatment in VUR patients. Although endoscopic VUR treatment is effective in reducing the inflammatory response, the persistence of significant abnormal levels of inflammatory cytokines (such as urinary MCP-1) at long term follow-up suggests that surgery alone may not completely treat the chronic renal inflammation evidenced in these children.
Descritores: Infecções Urinárias/diagnóstico
Refluxo Vesicoureteral/urina
Quimiocina CCL2/urina
Fator de Crescimento Epidérmico/urina
-Infecções Urinárias/etiologia
Refluxo Vesicoureteral/cirurgia
Refluxo Vesicoureteral/complicações
Biomarcadores/urina
Estudos de Casos e Controles
Estudos Prospectivos
Limites: Humanos
Masculino
Feminino
Lactente
Pré-Escolar
Criança
Responsável: BR1.1 - BIREME


  3 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-896979
Autor: Silva, Déborah Maria Moreira da; Pinheiro, Laila; Azevedo, Cristiano Schetini; Costa, Guilherme de Paula; Talvani, André.
Título: Influence of environmental enrichment on the behavior and physiology of mice infected by trypanosoma cruzi
Fonte: Rev. Soc. Bras. Med. Trop;50(3):341-349, May-June 2017. tab, graf.
Idioma: en.
Resumo: Abstract INTRODUCTION: Enriched environments normally increase behavioral repertoires and diminish the expression of abnormal behaviors and stress-related physiological problems in animals. Although it has been shown that experimental animals infected with microorganisms can modify their behaviors and physiology, few studies have evaluated how environmental enrichment affects these parameters. This study aimed to evaluate the effects of environmental enrichment on the behavior and physiology of confined mice infected with Trypanosoma cruzi. METHODS: The behaviors of 20 T. cruzi-infected mice and 20 non-infected mice were recorded during three treatments: baseline, enrichment, and post-enrichment. Behavioral data were collected using scan sampling with instantaneous recording of behavior every 30s, totaling 360h. Plasma TNF, CCL2, and IL-10 levels and parasitemia were also evaluated in infected enriched/non-enriched mice. Behavioral data were evaluated by Friedman's test and physiological data by one-way ANOVA and area under the curve (AUC) analysis. RESULTS: Results showed that environmental enrichment significantly increased exploratory behaviors and diminished inactivity. The use of environmental enrichment did not diminish circulating levels of TNF and IL-10 but diminished circulating levels of CCL2 and parasitemia. CONCLUSIONS: Positive behavioral and physiological effects of environmental enrichment were observed in mice living in enriched cages. Thus, environmental enrichment improved the welfare of these animals.
Descritores: Comportamento Animal/fisiologia
Doença de Chagas/fisiopatologia
Meio Ambiente
-Fatores de Tempo
Fator de Necrose Tumoral alfa
Interleucina-10/sangue
Doença de Chagas/sangue
Parasitemia/fisiopatologia
Quimiocina CCL2/sangue
Modelos Animais de Doenças
Camundongos
Camundongos Endogâmicos C57BL
Limites: Animais
Masculino
Responsável: BR1.1 - BIREME


  4 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-950828
Autor: Xu, Yuan-kun; Ke, Yan; Wang, Bin; Lin, Jian-hao.
Título: The role of MCP-1-CCR2 ligand-receptor axis in chondrocyte degradation and disease progress in knee osteoarthritis
Fonte: Biol. Res;48:1-8, 2015. ilus, graf, tab.
Idioma: en.
Projeto: Beijing Municipal Science and Technology Commission; . The National Natural Science Fund.
Resumo: BACKGROUND: Osteoarthritis (OA) is a common arthritic disease and multifactorial whole-joint disease. Interactions of chemokines and OA is inadequately documented. RESULTS: In vivo and in vitro studies were conducted to investigate monocyte chemoattractant protein 1 (MCP-1) and receptor chemokine (C-C motif) receptor 2 (CCR2) in chondrocyte degradation and cartilage degeneration. Chondrocytes from 16 OA patients and 6 normal controls were involved in this study. After stimulation of MCP-1, the expression of MCP-1 and CCR2 increased significantly (P < 0.001) and the expression of MMP-13 also increased (P < 0.05). MCP-1 stimulation also induced (or enhanced) the apoptosis of OA chondrocytes (P < 0.05). Additionally, the degradation of cartilage matrix markers (metalloproteinase 3 and 13, MMP3 and MMP13) in the culture medium of normal chondrocytes was also assessed. Furthermore, intra-articular injection of MCP-1 in mouse knees induced cartilage degradation and the CCR2 antagonist did not impede cartilage destroy in rats knees of monosodium iodoacetate (MIA) model. CONCLUSIONS: The results of this study demonstrate that the MCP-1-CCR2 ligand-receptor axis plays a special role in the initiation and progression of OA pathology. Patients with ambiguous etiology can gain some insight from the MCP-1-CCR2 ligand-receptor axis.
Descritores: Quimiocina CCL2/metabolismo
Condrócitos/metabolismo
Osteoartrite do Joelho/fisiopatologia
Receptores CCR2/metabolismo
-Membrana Sinovial/citologia
Técnicas In Vitro
Ensaio de Imunoadsorção Enzimática
Ratos Sprague-Dawley
Apoptose/fisiologia
Progressão da Doença
Quimiocina CCL2/genética
Metaloproteinase 3 da Matriz/metabolismo
Condrócitos/enzimologia
Ácido Iodoacético
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Metaloproteinase 13 da Matriz/metabolismo
Receptores CCR2/antagonistas & inibidores
Receptores CCR2/genética
Fibroblastos/metabolismo
Proteínas Matrilinas/metabolismo
Camundongos Endogâmicos C57BL
Limites: Humanos
Animais
Masculino
Feminino
Adolescente
Pessoa de Meia-Idade
Idoso
Camundongos
Ratos
Adulto Jovem
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: CL1.1 - Biblioteca Central


  5 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-950876
Autor: Zhang, Li; Tan, Jinyun; Jiang, Xiaoping; Qian, Weiwei; Yang, Ting; Sun, Xijun; Chen, Zhaohui; Zhu, Qiwen.
Título: Neuron-derived CCL2 contributes to microglia activation and neurological decline in hepatic encephalopathy
Fonte: Biol. Res;50:26, 2017. graf.
Idioma: en.
Projeto: Lanzhou Talent Innovation and Entrepreneurship Project.
Resumo: BACKGROUND: CCL2 was up-regulated in neurons and involved in microglia activation and neurological decline in mice suffering from hepatic encephalopathy (HE). However, no data exist concerning the effect of neuron-derived CCL2 on microglia activation in vitro. METHODS: The rats were pretreated with CCL2 receptor inhibitors (INCB or C021, 1 mg/kg/day i.p.) for 3 days prior to thioacetamide (TAA) administration (300 mg/kg/day i.p.) for inducing HE model. At 8 h following the last injection (and every 4 h after), the grade of encephalopathy was assessed. Blood and whole brains were collected at coma for measuring CCL2 and Iba1 expression. In vitro, primary neurons were stimulated with TNF-α, and then the medium were collected for addition to microglia cultures with or without INCB or C021 pretreatment. The effect of the medium on microglia proliferation and activation was evaluated after 24 h. RESULTS: CCL2 expression and microglia activation were elevated in the cerebral cortex of rats received TAA alone. CCL2 receptors inhibition improved neurological score and reduced cortical microglia activation. In vitro, TNF-α treatment induced CCL2 release by neurons. Medium from TNF-α stimulated neurons caused microglia proliferation and M1 markers expression, including iNOS, COX2, IL-6 and IL-1ß, which could be suppressed by INCB or C021 pretreatment. The medium could also facilitate p65 nuclear translocation and IκBα phosphorylation, and NF-κB inhibition reduced the increased IL-6 and IL-1ß expression induced by the medium. CONCLUSION: Neuron-derived CCL2 contributed to microglia activation and neurological decline in HE. Blocking CCL2 or inhibiting microglia excessive activation may be potential strategies for HE.
Descritores: Encefalopatia Hepática/metabolismo
Microglia/metabolismo
Quimiocina CCL2/metabolismo
Receptores de Quimiocinas/antagonistas & inibidores
Neurônios/metabolismo
-Tioacetamida
Expressão Gênica
Encefalopatia Hepática/induzido quimicamente
Encefalopatia Hepática/terapia
Interleucina-6/metabolismo
Microglia/efeitos dos fármacos
Quimiocina CCL2/antagonistas & inibidores
Meios de Cultura/farmacologia
Modelos Animais de Doenças
Doenças do Sistema Nervoso
Limites: Animais
Ratos
Responsável: CL1.1 - Biblioteca Central


  6 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-838717
Autor: Ritter, Alessandra Mileni Versuti; Faria, Ana Paula Cabral de; Sabbatini, Andrea; Corrêa, Nathalia Batista; Brunelli, Veridiana; Modolo, Rodrigo; Moreno, Heitor.
Título: MCP-1 Levels are Associated with Cardiac Remodeling but not with Resistant Hypertension / Níveis de MCP-1 estão Associados com Remodelamento Cardíaco mas não com Hipertensão Resistente
Fonte: Arq. bras. cardiol;108(4):331-338, Apr. 2017. tab, graf.
Idioma: en.
Resumo: Abstract Background: Hypertension is a chronic, low-grade inflammation process associated with the release of cytokines and development of target organ damage. Deregulated monocyte chemoattractant protein-1 (MCP-1) levels have been associated with high blood pressure and cardiovascular complications; however, the mechanisms involved are complex and not fully understood. Objective: This study aimed to compare the levels of MCP-1 in patients with resistant (RH) versus mild-to-moderate (HTN) hypertension and their association with the presence or absence of left ventricular hypertrophy (LVH) in all hypertensive subjects. Methods: We enrolled 256 hypertensive subjects: 120 RH and 136 HTN, investigating the relationship between circulating MCP-1 levels and blood pressure, biochemical data, hematologic profile, and cardiac damage within the RH and HTN groups. Plasma MCP-1 levels were measured by ELISA and LVH was assessed by echocardiography. Results: We found no difference in MCP-1 levels between RH and HTN subjects. On the other hand, we encountered lower MCP-1 levels in patients with LVH (105 pg/mL [100 - 260 pg/mL] versus 136 pg/mL (100 - 200 pg/mL), p = 0.005, respectively] compared with those without LVH. A logistic regression model adjusted for body mass index (BMI), age, race, aldosterone levels, and presence of diabetes and RH demonstrated that median levels of MCP-1 (2.55 pg/mL [1.22 - 5.2 pg/mL], p = 0.01) were independently associated with LVH in the entire hypertensive population. Conclusion: Since MCP-1 levels were similar in both RH and HTN subjects and decreased in hypertensive patients with existing LVH, our study suggests a possible downregulation in MCP-1 levels in hypertensive individuals with LVH, regardless of hypertension strata.

Resumo Fundamentos: A hipertensão arterial é um processo crônico de baixo grau inflamatório, associado com liberação de citocinas e desenvolvimento de lesão em órgãos-alvo. A desregulação dos níveis de proteína quimiotática de monócitos-1 (MCP-1) tem sido associada com elevação da pressão arterial e complicações cardiovasculares; porém, os mecanismos envolvidos são complexos e ainda não foram inteiramente elucidados. Objetivo: O objetivo deste estudo foi comparar os níveis de MCP-1 em pacientes com hipertensão resistente (HR) versus pacientes com hipertensão de grau leve a moderado (HAS) e sua associação com a presença ou ausência de hipertrofia ventricular esquerda (HVE) em todos os indivíduos hipertensos. Métodos: Foram incluídos 256 indivíduos hipertensos: 120 com HR e 136 com HAS. Foi investigada a relação entre os níveis circulantes de MCP-1 e pressão arterial, dados bioquímicos, perfil hematológico e dano cardíaco nos grupos HR e HAS. Os níveis plasmáticos de MCP-1 foram medidos por ELISA e a HVE foi avaliada por ecocardiografia. Resultados: Não encontramos diferença nos níveis de MCP-1 entre indivíduos com HR e HAS. Por outro lado, encontramos níveis mais baixos de MCP-1 em pacientes com HVE (105 pg/mL [100 - 260 pg/mL] versus 136 pg/mL [100 - 200 pg/mL], respectivamente, p = 0,005] em comparação a pacientes sem HVE. Um modelo de regressão logística ajustado para o índice de massa corporal (IMC), idade, raça, níveis de aldosterona e presença de diabetes e HR mostrou que os níveis medianos de MCP-1 (2,55 pg/mL [1,22 - 5,2 pg/mL], p = 0,01) estiveram independentemente associados com HVE em toda a população de hipertensos. Conclusão: Como os níveis de MCP-1 foram semelhantes em indivíduos tanto com HR quanto HAS e estiveram diminuídos em pacientes hipertensos com HVE, nosso estudo sugere uma possível redução nos níveis de MCP-1 em indivíduos hipertensos com HVE, independe do grau da hipertensão.
Descritores: Hipertrofia Ventricular Esquerda/fisiopatologia
Quimiocina CCL2/análise
Remodelação Ventricular/fisiologia
Hipertensão/fisiopatologia
-Índice de Gravidade de Doença
Estudos Transversais
Monitorização Ambulatorial da Pressão Arterial
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Estudo Observacional
Responsável: BR1.1 - BIREME


  7 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-838797
Autor: Esposito, Evangelina; Aldrees, Sultan; Mastromonaco, Christina; Zoroquiain, Pablo; Vila, Natalia; Logan, Patrick T; Hari, Shriya; Burnier, Miguel N.
Título: Evaluation of nicotinamide as an anti-inflammatory and anti-angiogenic agent in uveal melanoma cell lines / Avaliação da nicotinamida como agente anti-inflamatório e anti-angiogênico em linhas celulares de melanoma uveal
Fonte: Arq. bras. oftalmol;80(2):74-77, Mar.-Apr. 2017. tab.
Idioma: en.
Resumo: ABSTRACT Purpose: To investigate the effect of nicotinamide on the secretion of pro-an giogenic and pro-inflammatory cytokines in uveal melanoma cell lines. Methods: Two human uveal melanoma cell lines (92.1 and OCM-1) were treated with nicotinamide (10 mmol/L) or control media for 48 hours in culture. The su perna tant from each culture was used in sandwich enzyme-linked immuno sorbent assay-based angiogenesis and inflammation arrays to evaluate the effects of exogenously administered nicotinamide on the secretion of a total of 20 pro-an gio genic and pro-inflammatory proteins. Results: Seven pro-angiogenic cytokines were detected under control conditions for both uveal melanoma cell lines. Treatment with nicotinamide resulted in a significant decrease in secretion of the following pro-angiogenic cytokines: angiogenin, angiopoietin-2, epidermal growth factor, and vascular epithelial growth factor-A in the 92.1 cells; basic fibroblast growth factor in the OCM-1 cells; and placenta growth factor in both cell lines. Among the pro-inflammatory proteins, monocyte chemotactic protein-1 and interleukin-8 were expressed in both untreated cell lines and both were significantly reduced when treated with nicotinamide. Conclusions: Results from this in vitro model suggest that nicotinamide may have anti-inflammatory and anti-angiogenic properties, which may open the possibility of using it as a chemopreventive agent for uveal melanoma; however, further studies including animal models are warranted.

RESUMO Objetivo: Acredita-se que a nicotinamida (NIC) seja capaz de diminuir a angiogênese induzida pelo fator de crescimento endotelial vascular (VEGF). Investigar os efeitos da nicotinamida sobre a secreção de citocinas pró-angiogênicas e pró-inflamatórias em linhagens de células de melanoma uveal humano (UM). Métodos: Duas linhagens de células humanas de UM (92,1 e OCM-1) foram tratadas com NIC (10 mmol/L) ou apenas com meio de cultura por 48 horas. O sobrenadante das culturas obtido após a administração de nicotinamida foi comparado com o sobrenadante das culturas controle quanto à expressão de 20 fatores pró-angiogênicos e pró-inflamatórios, pela técnica de enzyme-linked immunosorbent assay (ELISA). Resultados: Sete citocinas pró-angiogênicas foram detectadas nas condições de controle em ambas as linhagens de células de UM. O tratamento com nicotinamida promoveu uma redução significativa da secreção das seguintes citocinas angiogênicas: Angiogenina, ANG2, EGF e VEGF-A em células 92.1; bFGF em células OCM-1; PIGF em ambas as linhagens celulares. Quanto às proteínas pró-inflamatórias, a expressão de MCP-1 e IL-8 foi significativamente reduzida com a administração de nicotinamida em relação às culturas de células que não receberam o tratamento. Conclusões: Nicotinamida apresenta propriedades anti-inflamatórias e anti-angiogênicas em modelo experimental in vitro. Tais efeitos sugerem a possibilidade de utilizar esta substância na quimioprevenção do UM. Entretanto, estudos com modelos experimentais in vivo são necessários para melhor avaliar o benefício do tratamento do UM com nicotinamida.
Descritores: Neoplasias Uveais/metabolismo
Citocinas/efeitos dos fármacos
Niacinamida/farmacologia
Inibidores da Angiogênese/farmacologia
Melanoma/metabolismo
Anti-Inflamatórios/farmacologia
-Ribonuclease Pancreático/efeitos dos fármacos
Neoplasias Uveais/irrigação sanguínea
Citocinas/metabolismo
Fator 2 de Crescimento de Fibroblastos/efeitos dos fármacos
Interleucina-8/efeitos dos fármacos
Quimiocina CCL2/efeitos dos fármacos
Linhagem Celular Tumoral
Angiopoietina-2/metabolismo
Fator de Crescimento Epidérmico/efeitos dos fármacos
Fator de Crescimento Placentário/efeitos dos fármacos
Melanoma/irrigação sanguínea
Limites: Humanos
Responsável: BR1.1 - BIREME


  8 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Boguszewski, Cesar L
Texto completo
Id: biblio-887553
Autor: Paiva, Eduardo S; Andretta, Aline; Batista, Emmanuelle Dias; Lobo, Márcia Maria Marques Teles; Miranda, Renata Costa de; Nisihara, Renato; Schieferdecker, Maria Eliana Madalozzo; Boguszewski, César L.
Título: Serum levels of leptin and adiponectin and clinical parameters in women with fibromyalgia and overweight/obesity
Fonte: Arch. endocrinol. metab. (Online);61(3):249-256, May-June 2017. tab.
Idioma: en.
Resumo: ABSTRACT Objectives The objectives of this study were to evaluate the serum levels of adipokines in women with fibromyalgia with and without overweight/obesity, and to correlate the adipokines levels with clinical parameters associated with fibromyalgia and adipose tissue mass (body fat). Subjects and methods The study included 100 women divided into four groups: (a) fibromyalgia and overweight/obesity; (b) fibromyalgia and normal weight; (c) controls and overweight/obesity; and (d) controls and normal weight. Patients and controls were evaluated for clinical, anthropometric, and fibromyalgia-related parameters. Assessments included serum levels of leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-1), and C-reactive protein (CRP). Levels of adipokines were further adjusted for fat mass. Results Fibromyalgia patients with overweight/obesity or normal weight had no differences in clinical parameters. Unadjusted leptin levels were lower in fibromyalgia patients than controls, a finding that was more remarkable in fibromyalgia patients with overweight/obesity. Leptin levels had no correlation with clinical parameters of fibromyalgia or inflammation markers (MCP-1 and CRP), and adiponectin levels showed no difference between groups. Conclusions No correlation was observed between adjusted leptin levels and clinical parameters of fibromyalgia. Patients with fibromyalgia and overweight/obesity presented lower levels of leptin than controls with overweight/obesity.
Descritores: Fibromialgia/sangue
Leptina/sangue
Sobrepeso/sangue
Adiponectina/sangue
-Qualidade de Vida
Valores de Referência
Proteína C-Reativa/análise
Biomarcadores/sangue
Fibromialgia/fisiopatologia
Índice de Massa Corporal
Estudos de Casos e Controles
Inquéritos e Questionários
Limiar da Dor
Estatísticas não Paramétricas
Quimiocina CCL2/sangue
Sobrepeso/fisiopatologia
Circunferência da Cintura
Limites: Humanos
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  9 / 17 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887629
Autor: Matia-García, Inés; Salgado-Goytia, Lorenzo; Ramos-Arellano, Luz Elena; Muñoz-Valle, José Francisco; Armenta-Solís, Adakatia; Garibay-Cerdenares, Olga Lilia; Ramírez, Mónica; Parra-Rojas, Isela.
Título: A possible association between the -2518 A>G MCP-1 polymorphism and insulin resistance in school children
Fonte: Arch. endocrinol. metab. (Online);62(1):79-86, Jan.-Feb. 2018. tab.
Idioma: en.
Resumo: ABSTRACT Objective Monocyte chemoattractant protein 1 (MCP-1) has been suggested to be involved in the pathophysiology of insulin resistance (IR); therefore, variants in the MCP-1 gene may contribute to the development of this disease. The aim of this study was to analyze the relationship of the -2518 A>G MCP-1 (rs1024611) gene polymorphism with insulin resistance in Mexican children. Subjects and methods A cross-sectional study was performed in 174 children, including 117 children without insulin resistance and 57 children with IR, with an age range of 6-11 years. Levels for serum insulin and high-sensitivity C-reactive protein were determined. The -2518 A>G MCP-1 polymorphism was identified by the polymerase chain reaction-restriction fragment length polymorphism method. Insulin resistance was defined as a HOMA-IR in the upper 75th percentile, which was ≥ 2.4 for all children. Results Genotype frequencies of the rs1024611 polymorphism for the insulin-sensitive group were 17% AA, 48% AG and 35% GG, and the frequency of G allele was 59%, whereas frequencies for the insulin-resistant group were 12% AA, 37% AG and 51% GG, and the frequency of G allele was 69%. The genotype and allele frequencies between groups did not show significant differences. However, the GG genotype was the most frequent in children with IR. The GG genotype was associated with insulin resistance (OR = 2.2, P = 0.03) in a genetic model. Conclusion The -2518 A>G MCP-1 gene polymorphism may be related to the development of insulin resistance in Mexican children.
Descritores: Resistência à Insulina/genética
Quimiocina CCL2/genética
Polimorfismo de Nucleotídeo Único/genética
-Marcadores Genéticos/genética
Estudos de Casos e Controles
Estudos Transversais
Predisposição Genética para Doença
Frequência do Gene
Genótipo
Limites: Humanos
Masculino
Feminino
Criança
Responsável: BR1.1 - BIREME


  10 / 17 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887651
Autor: Lin, Yang; Ye, Shandong; He, Yuanyuan; Li, Sumei; Chen, Yan; Zhai, Zhimin.
Título: Short-term insulin intensive therapy decreases MCP-1 and NF-κB expression of peripheral blood monocyte and the serum MCP-1 concentration in newlydiagnosed type 2 diabetics
Fonte: Arch. endocrinol. metab. (Online);62(2):212-220, Mar.-Apr. 2018. tab, graf.
Idioma: en.
Projeto: Natural Science Foundation; . Natural Science Research Project.
Resumo: ABSTRACT Objective To observe the effect of short-term insulin intensive treatment on the monocyte chemoattractant protein-1 (MCP-1) as well as on the nuclear factor-kappa B (NF-κB) expression of peripheral blood monocyte. This is also in addition to observing the serum MCP-1 level in newlydiagnosed type 2 diabetic patients and probing its anti-inflammation effects. Subjects and methods Twenty newly-diagnosed type 2 diabetic patients were treated with an insulin intensive treatment for 2 weeks. MCP-1 and NF-κB expression on the monocyte surface were measured with flow cytometry, the serum MCP-1 level was measured by enzyme linked immunosorbent assay (ELISA) during pretreatment and post-treatment. Results After 2 weeks of the treatment, MCP-1 and NF-κB protein expression of peripheral blood monocyte and serum MCP-1 levels decreased significantly compared with those of pre-treatment, which were (0.50 ± 0.18)% vs (0.89 ± 0.26)% (12.22 ± 2.80)% vs (15.53 ± 2.49)% and (44.53 ± 3.97) pg/mL vs (49.53 ± 3.47) pg/mL, respectively (P < 0.01). The MCP-1 expression on monocyte surface had a significant positive relationship with serum MCP-1 levels (r = 0.47, P < 0.01). Conclusions Short-term insulin intensive therapy plays a role in alleviating the increased inflammation reaction in type 2 diabetics.
Descritores: Monócitos/química
NF-kappa B/efeitos adversos
Quimiocina CCL2/efeitos dos fármacos
Diabetes Mellitus Tipo 2/tratamento farmacológico
Inflamação/prevenção & controle
Insulina/administração & dosagem
-Ensaio de Imunoadsorção Enzimática
Estudos de Casos e Controles
NF-kappa B/sangue
Quimiocina CCL2/sangue
Diabetes Mellitus Tipo 2/sangue
Citometria de Fluxo
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde